Natera/$NTRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
4,429
ISIN
US6323071042
Website
Natera Metrics
BasicAdvanced
$20B
-
-$1.48
1.73
-
Price and volume
Market cap
$20B
Beta
1.73
52-week high
$183.00
52-week low
$92.14
Average daily volume
1.2M
Financial strength
Current ratio
3.873
Quick ratio
3.582
Long term debt to equity
8.313
Total debt to equity
15.778
Interest coverage (TTM)
-26.52%
Profitability
EBITDA (TTM)
-197.515
Gross margin (TTM)
61.79%
Net profit margin (TTM)
-10.36%
Operating margin (TTM)
-12.41%
Effective tax rate (TTM)
-0.23%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-8.87%
Return on equity (TTM)
-18.66%
Valuation
Price to revenue (TTM)
10.039
Price to book
15.72
Price to tangible book (TTM)
15.72
Price to free cash flow (TTM)
215.767
Free cash flow yield (TTM)
0.46%
Free cash flow per share (TTM)
66.45%
Growth
Revenue change (TTM)
51.50%
Earnings per share change (TTM)
-52.51%
3-year revenue growth (CAGR)
40.00%
10-year revenue growth (CAGR)
26.15%
3-year earnings per share growth (CAGR)
-36.85%
10-year earnings per share growth (CAGR)
2.91%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Bulls say / Bears say
Natera's revenue has grown at a compounded annual rate of 40.9% over the past five years, indicating strong market demand for its products. (stockstory.org)
The company has secured Medicare coverage for its Signatera™ genome-based assay, potentially expanding its market reach and revenue streams. (businesswire.com)
Analysts have set an average 12-month price target of $185.56 for Natera, suggesting a potential upside of approximately 14.71% from its current price. (stockanalysis.com)
Natera's price-to-sales ratio of 11.4x is higher than many peers in the biotech industry, raising concerns about overvaluation. (simplywall.st)
The company reported an operating margin of -50.92%, indicating significant challenges in achieving profitability. (gurufocus.com)
Despite strong revenue growth, Natera's return on equity stands at -80.57%, reflecting inefficiencies in generating returns for shareholders. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Natera News
AllArticlesVideos
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
Business Wire·2 weeks ago
Nearly 16 % of Druckenmiller's Money Now Rides on This Stock
24/7 Wall Street·1 month ago
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $20B as of July 18, 2025.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of July 18, 2025.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of July 18, 2025.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.